Skip to main content
Premium Trial:

Request an Annual Quote

TorreyPines, Eisai Extend Genetic Research Collaboration for Alzheimer's

NEW YORK (GenomeWeb) - TorreyPines Therapeutics and Eisai have extended an agreement to identify and validate genes that may be used as targets for Alzheimer's drug compounds, TorreyPines said yesterday.
The research collaboration, which the companies began in 2005, is using whole-genome family-based association screening to identify genes associated with Alzheimer's disease.
TorreyPines, based in La Jolla, Calif., will receive an upfront payment and funding for the research for another year, and Eisai will have exclusive rights for first negotiation and refusal for gene targets that come from the research.
TorreyPines said the companies also are involved in a separate agreement to find novel compounds that may be used to treat Alzheimer's disease.
Financial terms of the agreement were not released.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.